Enterprise Value
-181.6M
Cash
386.6M
Avg Qtr Burn
-24.27M
Short % of Float
8.12%
Insider Ownership
6.54%
Institutional Own.
95.37%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MAVYRET (Glecaprevir) Details HCV (Hepatitis C Virus) | Approved Quarterly sales | |
EDP-938 (N-inhibitor) Details Viral infection, Respiratory syncytial virus, Respiratory virus | Phase 2b Data readout | |
EDP-235 Details Viral infection, COVID-19 | Phase 2 Update | |
EDP-514 (HBV Core inhibitor) Details Hepatitis B | Phase 2 Initiation | |
EDP-323 Details Viral infection, Respiratory syncytial virus, Respiratory virus | Phase 2a Data readout | |
EDP-305 (FXR Agonist) Details Non-alcoholic steatohepatitis | Failed Discontinued | |
ENP-297 (FXR inhibitor) Details Non-alcoholic steatohepatitis | Failed Discontinued |